$CGEM

Cullinan Therapeutics (CGEM) reported Phase 3 REZILIENT3 results, showing zipalertinib plus chemotherapy achieved 14.5 months median PFS vs. 8.5 months for chemotherapy alone in NSCLC patients. While efficacy is promising, high adverse event rates raise toxicity concerns. The company shares U.S. profits with Taiho Pharmaceutical.

Cullinan Therapeutics (CGEM) shares fell 6.3% despite positive Phase 3 trial results for zipalertinib in lung cancer treatment. The REZILIENT3 trial met its primary endpoint, showing a 6.0-month improvement in median progression-free survival compared to chemotherapy alone. The company plans to discuss the results with health authorities. According to Cullinan, the trial enrolled 279 patients with advanced NSCLC.

Cullinan Therapeutics reported that its drug zipalertinib, combined with chemotherapy, showed a median progression-free survival of 14.5 months compared to 8.5 months with chemotherapy alone in the Phase 3 REZILIENT3 trial. The study included 279 patients with EGFR ex20ins NSCLC. The combination also achieved a higher objective response rate (65.0% vs. 40.3%) and longer median duration of response (14.2 vs. 9.9 months). Safety data showed higher Grade ≥3 adverse events with the combination, prim

Cullinan Therapeutics' Zipalertinib plus chemotherapy improved progression-free survival and response rates in first-line EGFR exon 20 insertion mutation NSCLC, according to the company. The treatment showed a manageable safety profile, supporting its potential as a first-line option.

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced positive Phase 3 REZILIENT3 trial results for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC. The combination showed a 6.0-month median PFS improvement (HR=0.50, P=0.00015) and higher response rates. Data were presented at WCLC 2026. The companies plan to discuss results with health authorities.

Cullinan Therapeutics (CGEM) will present Phase 3 REZILIENT3 trial data on zipalertinib plus chemotherapy for NSCLC at WCLC 2026. The trial met its primary endpoint of progression-free survival. The company will host an investor event on September 14, 2026, to discuss the results.

Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD

Cullinan Therapeutics (CGEM) shares rose 6.6% after positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant progression-free survival benefits. This positions zipalertinib as a potential first-line treatment for a specific subset of non-small cell lung cancer patients, supporting planned U.S. regulatory filings. Cullinan Therapeutics has no revenue but holds a high-risk pipeline with potential in oncology and autoimmune diseases.

Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics (CGEM) reported positive Phase 3 trial results for zipalertinib in lung cancer. The trial met its primary endpoint, showing significant improvement in progression-free survival for patients with EGFR exon 20 insertion mutations. The companies plan to submit full results for presentation at an upcoming medical conference and pursue U.S. regulatory approval. Zipalertinib would compete with Johnson & Johnson's amivantamab (Rybrevant) i

Taiho Oncology and Cullinan Therapeutics (CGEM) announced that Phase 3 REZILIENT3 trial data for zipalertinib plus chemotherapy in EGFR exon 20 insertion mutation NSCLC will be presented at the 2026 IASLC World Conference. The trial met its primary endpoint of progression-free survival. Zipalertinib is an investigational EGFR inhibitor.